Targeting a polyepitope protein incorporating multiple class II- restricted vital epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design

Journal of Virology

Volumn 72, Issue 3, 1998, Pages 2246-2252

  Thomson, Scott A ^a   Burrows, Scott R ^a   Misko, Ihor S ^a   Moss, Denis J ^a   Coupar, Barbara E H ^b   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HELA CELL; HUMAN; HUMAN CELL; INFLUENZA VIRUS; LYSOSOME; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY CELL; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS;

EID: 0031911648     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.3.2246-2252.1998     Document Type: Article

References (41)

1. Andrew, M. E., D. B. Boyle, B. E. Coupar, P. L. Whitfeld, G. W. Both, and A. R. Bellamy. 1987. Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralizing antibodies. J. Virol. 61:1054-1060.
2. Bikoff, E. K. 1992. Formation of complexes between self-peptides and MHC class II molecules in cells defective for presentation of exogenous protein antigens. J. Immunol. 149:1-8.
3. Blum, J. S., and P. Cresswell. 1988. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad. Sci. USA 85:3975-3979.
4. Boyle, D. B., B. E. Coupar, and G. W. Both. 1985. Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 35:169-177.
5. Braciale, T. J., L. A. Morrison, M. T. Sweetser, J. Sambrook, M. J. Gething, and V. L. Braciale. 1987. Antigen presentation pathways to class I and class II. Immunol. Rev. 98:95-114.
6. Chalfie, M., Y. Tu, G. Euskirchen, W. W. Ward, and D. C. Prasher. 1994. Green fluorescent protein as a marker for gene expression. Science 263:802-805.
7. Coupar, B. E., M. E. Andrew, G. W. Both, and D. B. Boyle. 1986. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 16:1479-1487.
8. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-293.
9. Cresswell, P. 1996. Invariant chain structure and MHC class II function. Cell 84:505-507.
10. Cubitt, A. B., R. Heim, S. R. Adams, A. E. Boyd, L. A. Gross, and R. Y. Tsien. 1995. Understanding, improving and using green fluorescent proteins. Trends Biochem. Sci. 20:448-445.
11. Eager, K. B., C. J. Hackett, W. U. Gerhard, J. Bennink, L. C. Eisenlohr, J. Yewdell, and R. P. Ricciardi. 1989. Murine cell lines stably expressing the influenza virus hemagglutinin gene introduced by a recombinant retrovirus vector are constitutive targets for MHC class I- and class II-restricted T lymphocytes. J. Immunol. 143:2328-2335.
12. Fleisher, G. R., M. Collins, and S. Fager. 1985. Humoral immune response in infectious mononucleosis. Late emergence of anti-EA (R) and the effects of corticosteroid therapy. J. Adolesc. Health Care 6:424-428.
13. Fukuda, M., J. Viitala, J. Matteson, and S. R. Carlsson. 1988. Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Comparison of their deduced amino acid sequences. J. Biol. Chem. 263:18920-18928.
14. Germain, R. N. 1986. Immunology. The ins and outs of antigen processing and presentation. Nature 322:687-689.
15. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
16. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epilopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
17. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
18. Khanna, R., S. R. Borrows, D. J. Moss, and S. L. Silins. 1996. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J. Virol. 70: 5357-5362.
19. Khanna, R., S. R. Burrows, A. Suhrbier, C. A. Jacob, H. Griffin, I. S. Misko, T. B. Sculley, M. Rowe, A. B. Rickinson, and D. J. Moss. 1993. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J. Immunol. 150: 5154-5162.
20. Khanna, R., S. R. Burrows, S. A. Thomson, D. J. Moss, P. Cresswell, P. Poulsen, and L. Cooper. 1997. Class I processing defective Burkitt's lymphoma cells are recognised efficiently by CD4+ EBV-specific CTL. J. Immunol. 157:3619-3625.
21. Khanna, R., C. A. Jacob, S. R. Barrows, M. G. Kurilla, E. Kief, I. S. Misko, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells. Immunology 74:504-510.
22. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41-49.
23. Lin, K. Y., F. G. Guarnieri, O. F. Staveley, H. I. Levitsky, J. T. August, D. M. Pardoll, and T. C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major hislocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26.
24. Morrison, L. A., V. L. Braciale, and T. J. Braciale. 1988. Antigen form influences induction and frequency of influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes. J. Immunol. 141:363-368.
25. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719-721.
26. Neefjes, J. J., V. Stollorz, P. J. Peters, H. J. Geuze, and H. L. Ploegh. 1990. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 61:171-183.
27. Nuchtern, J. G., W. E. Biddison, and R. D. Klausner. 1990. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343:74-76.
28. Persson, H., H. Jornvall, and J. Zabielski. 1980. Multiple mRNA species for the precursor to an adenovirus-encoded glycoprotein: identification and structure of the signal sequence. Proc. Natl. Acad. Sci. USA 77:6349-6353.
29. Pines, J. 1995. GFP in mammalian cells. Trends Genet. 11:326-327.
30. Rizzuto, R., M. Brini, P. Pizzo, M. Murgia, and T. Pozzan. 1995. Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells. Curr. Biol. 5:635-642.
31. Rowell, J. F., A. L. Ruff, F. G. Guarnieri, O. Staveley, X. Lin, J. Tang, J. T. August, and R. F. Siliciano. 1995. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J. Immunol. 155:1818-1828.
32. Sanderson, S., K. Frauwirth, and N. Shastri. 1995. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. USA 92:7217-7221.
33. Schmidt, C. W., and I. S. Misko. 1995. The ecology and pathology of Epstein-Barr virus. Immunol. Cell Biol. 73:489-504.
34. Strubin, M., C. Berte, and B. Mach. 1986. Alternative splicing and alternative initiation of translation explain the four forms of the Ia antigen-associated invariant chain. EMBO J. 5:3483-3488.
35. Sweetser, M. T., L. A. Morrison, V. L. Braciale, and T. J. Braciale. 1989. Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature 342:180-182.
36. Thomson, S., S. Elliott, M. Sherritt, K. W. Sproat, B. E. Coupar, A. A. Scalzo, C. A. Forbes, A. Ladhams, X. Y. Mo, R. Tripp, P. C. Doherty, D. J. Moss, and A. Suhrbier. Recombinant polyepitope vaccines for the delivery of multiple CD8+ cytotoxic T cell epitopes. J. Immunol., in press.
37. Thomson, S. A., R. Khanna, J. Gardner, S. R. Burrows, B. Coupar, D. J. Moss, and A. Suhrbier. 1995. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 92:5845-5849.
38. Weiss, S., and B. Bogen. 1991. MHC class II-restricted presentation of intracellular antigen. Cell 64:767-776.
39. White, C. A., S. M. Cross, M. G. Kurilla, B. M. Kerr, C. Schmidt, I. S. Misko, R, Khanna, and D. J. Moss. 1996. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 219:489-492.
40. Wu, T. C., F. G. Guarnieri, O. F. Staveley, R. P. Viscidi, H. I. Levitsky, L. Hedrick, K. R. Cho, J. T. August, and D. M. Pardoll. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 92:11671-11675.
41. Yewdell, J. W., and J. R. Bennink. 1989. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 244: 1072-1075.